Cor Vasa 2009, 51(9):584-589 | DOI: 10.33678/cor.2009.143

Heart failure (and not only heart failure) and atrial fibrillation: an opening gap between evidence and practice

Martin Fiala
Oddělení kardiologie, Kardiocentrum, Nemocnice Podlesí a. s., Třinec, Česká republika

Atrial fibrillation (AF) has become a major medical and socio-economic challenge. Restoration and maintenance of sinus rhythm is associated with an improved quality of life and prolonged survival; however, it is difficult to achieve in routine practice. This article addresses the role of antiarrhythmic drugs, AV junction ablation with cardiac pacing, and selective ablation while comparing them in the treatment of AF and heart failure. The issues of electric, mechanical, and structural myocardial remodeling and, possibly, reverse remodeling, and the potential of individual therapeutic methods to affect these processes are also discussed. Finally, the incidence of thromboembolic events after selective catheter ablation is compared with the efficacy of routine anticoagulation therapy.

Keywords: Atrial fibrillation; Treatment; Heart failure; Myocardial remodeling; Thromboembolic complication

Published: September 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Fiala M. Heart failure (and not only heart failure) and atrial fibrillation: an opening gap between evidence and practice. Cor Vasa. 2009;51(9):584-589. doi: 10.33678/cor.2009.143.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Tsang TS, Petty GW, Barnes ME, et al. The prevalence of atrial fibrillation in incident stroke cases and matched population controls in Rochester, Minnesota: changes over three decades. J Am Coll Cardiol 2003;42: 93-100. Go to original source...
    2. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projection for future prevalence. Circulation 2006;114:119-25. Go to original source... Go to PubMed...
    3. Lábrová R, Špinar J. Srdeční selhání a fibrilace síní. Cor Vasa 2008;50: 385-92. Go to original source...
    4. Dries DL, Aarons D, Exner DV, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular dysfunction. A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703. Go to original source...
    5. Pedersen OD, Bagger H, Keller N, et al. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: A Danish investigators of arrhythmia and mortality on dofetilide (Diamond) substudy. Circulation 2001;104:292-6. Go to original source...
    6. The Atrial Fibrillation Follow up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825-33. Go to original source...
    7. Hohnloser SH, Kuck KH, Lilienthal J, et al. Rhythm or rate control in atrial fibrillation-pharmacological intervention in atrial fibrillation (PIAF): a randomized trial. Lancet 2000;356:1789-94. Go to original source...
    8. Carlsson J, Miketic S, Windler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: STAF (strategies of treatment of atrial fibrillation) study. J Am Coll Cardiol 2003;41:1690-6. Go to original source...
    9. Van Gelder IC, Hagens VE, Bosker HA, et al. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation (RACE) Study Group: N Engl J Med 2002;347:1834-40. Go to original source...
    10. The AFFIRM Investigators. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109;1509-13. Go to original source... Go to PubMed...
    11. Roy D, Takajic M, Dorian P, et al. Amiodarone to prevent recurrence of atrial fibrillation. N Engl J Med 2000;342:913-20. Go to original source... Go to PubMed...
    12. Singh BN, Singh SN, Reda DJ, et al. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352:1861-72. Go to original source... Go to PubMed...
    13. Wazni OM, Marrouche NF, Martin DO, et al. Radiofrequency ablation vs. antiarrhythmic drugs as first-line treatment of symptomatic atrial fibrillation: a randomized trial. JAMA 2005;293:2634-40. Go to original source... Go to PubMed...
    14. Pappone C, Augello G, Sala S, et al. A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. The APAF study. J Am Coll Cardiol 2006;48:2340-7. Go to original source... Go to PubMed...
    15. Stabile G, Bertaglia E, Senatore G, et al. Catheter ablation treatment in patients with drug-refractory atrial fibrillation: a prospective multi-centre, randomized, controlled study (Catheter Ablation For The Cure Of Atrial Fibrillation Study). Eur Heart J 2006;27:216-21. Go to original source... Go to PubMed...
    16. Jaïs P, Cauchemez B, Macle L, et al. Catheter ablation versus antiarrhythmic drugs for atrial fibrillation: the A4 study. Circulation 2008;118:2498-505. Go to original source... Go to PubMed...
    17. Hsu LF, Jaïs P, Sanders P, et al. Catheter ablation for atrial fibrillation in congestive heart failure. N Engl J Med 2004;351:2373-83. Go to original source... Go to PubMed...
    18. Gentlesk PJ, Sauer WH, Gerstenfeld EP, et al. Reversal of left ventricular dysfunction following ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007;18:9-14. Go to original source... Go to PubMed...
    19. Nademanee K, Schwab MC, Kosar EM, et al. Clinical outcomes of catheter ablation for high-risk patients with atrial fibrillation. J Am Coll Cardiol 1008;51:843-9. Go to original source... Go to PubMed...
    20. Brignole M, Gianfranchi L, Menozzi C, et al. Influence of atrioventricular junction radiofrequency ablation in patients with chronic atrial fibrillation and flutter on quality of life and cardiac performance. J Am Coll Cardiol 1994;74:242-6. Go to original source... Go to PubMed...
    21. Brignole M, Gianfranchi L, Menozzi C, et al. Assessment of atrioventricular junction ablation and DDDR mode-switching pacemaker versus pharmacological treatment in patients with severely symptomatic paroxysmal atrial fibrillation: a randomized, controlled study. Circulation 1997;96: 2617-24. Go to original source...
    22. Brignole M, Menozzi C, Gianfranchi L, et al. Assessment of atrioventricular junction ablation and VVIR pacemaker versus pharmacological treatment in patients with heart failure and chronic atrial fibrillation: a randomized, controlled study. Circulation 1998;96:2617-24. Go to original source...
    23. Brignole M, Gianfranchi L, Menozzi C, et al. Prospective randomized study of atrioventricular ablation and mode switching, dual chamber pacemaker implantation versus medical therapy in drug resistant paroxysmal atrial fibrillation. The PAF study. Paroxysmal Atrial Fibrillation. Europace 1999;1:15-9. Go to original source... Go to PubMed...
    24. Marshall HJ, Harris ZI, Griffith MJ, et al. Prospective randomized study of ablation and pacing versus medical therapy for paroxysmal atrial fibrillation: effects of pacing mode and mode-switch algorithm. Circulation 1999;97: 1587-92. Go to original source...
    25. Weerasooryia R, Davis M, Powel A, et al. The Australian Intervention Randomized Control of Rate in Atrial Fibrillation Trial (AIRCRAFT). J Am Coll Cardiol 2003;41:1697-702. Go to original source...
    26. Levy T, Walker S, Mason M, et al. Importance of rate control of rate regulation for improving exercise capacity and quality of life in patients with permanent atrial fibrillation and normal left atrial function: a randomized controlled study. Heart 2001;85:171-8. Go to original source...
    27. Leon AR, Greenberg JM, Kanuru N, et al. Cardiac resynchronization in patients with congestive heart failure and chronic atrial fibrillation. Effect of upgrading to biventricular pacing after chronic right ventricular pacing. J Am Coll Cardiol 2002;39:1258-63. Go to original source...
    28. Gasparini M, Auricchio A, Regoli F, et al. Four-year efficacy of cardiac resynchronization therapy on exercise tolerance and disease progression. J Am Coll Cardiol 2006;48:734-43. Go to original source... Go to PubMed...
    29. Gasparini M, Auricchio A, Metra M, et al. Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation. Eur Heart J 2008;29:1644-52. Go to original source... Go to PubMed...
    30. Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: results from the Multisite Stimulation in Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111-8. Go to original source...
    31. Linde C, Braunschweig F, Gadler F, et al. Long-term improvements in quality of life by biventricular pacing in patients with chronic heart failure: results from the Multisite Stimulation in Cardiomyopathy study (MUSTIC). Am J Cardiol 2003;91:1090-5. Go to original source...
    32. Leclercq C, Walker S, Linde C, et al. Comparative effects of permanent biventricular and right atrial pacing in heart failure patients with chronic atrial fibrillation. Eur Heart J 2002;23:1780-7. Go to original source... Go to PubMed...
    33. Brignole M, Gammage M, Puggioni E, et al. Comparative assessment of right, left, and biventgricular pacing in patients with permanent atrial fibrillation. Eur Heart J 2005;26:712-22. Go to original source... Go to PubMed...
    34. Doshi RN, Daoud EG, Fellows C, et al. Left ventricular-based cardiac stimulation post AV nodal ablation evaluation (the PAVE study). J Cardiovasc Electrophysiol 2005;16:1160-5.35. Go to original source... Go to PubMed...
    35. Khan MN, Jaïs P, Cummings JE, et al. Pulmonary-Vein Isolation for atrial fibrillation with heart failure. N Engl J Med 2008;359:1778-85. Go to original source... Go to PubMed...
    36. Goette A, Staack T, Rocken C, et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000;35:1669-77. Go to original source...
    37. Verheule S, Sato T, Everett T, et al. Increased vulnerability to atrial fibrillation in transgenic mice with selective atrial fibrosis caused by overexpression of TGF-beta1. Circ Res 2004;94:1458-65. Go to original source... Go to PubMed...
    38. Aviles RJ, Martin DO, Apperson-Hansen C, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003;108:3006-10. Go to original source... Go to PubMed...
    39. Thomas L, Boyd A, Thomas SP, et al. Atrial structural remodelling and restoration of atrial contraction after linear ablation for atrial fibrillation. Eur Heart J 2003;24:1942-51. Go to original source... Go to PubMed...
    40. Lonnerholm S, Blomstrom P, Nilsson L, et al. Atrial size and transport function after the Maze III procedure for paroxysmal atrial fibrillation. Ann Thorac Surg 2002;73:107-11. Go to original source...
    41. Verma A, Kilicaslan F, Adams JR, et al. Extensive ablation during pulmonary vein isolation has no adverse impact on left atrial function. J Cardiovasc Electrophysiol 2006;17:741-6. Go to original source... Go to PubMed...
    42. Tsao HM, Wu MH, Huang BH, et al. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insights from long-term follow-up of three-dimensional magnetic resonance imaging. J Cardiovasc Electrophysiol 2005;16:7-12. Go to original source... Go to PubMed...
    43. Fiala M, Chovančík J, Nevřalová R, et al. Termination of long-lasting persistent versus short-lasting persistent and paroxysmal atrial fibrillation by ablation. Pac Clin Electrophysiol 2008;31:985-97. Go to original source... Go to PubMed...
    44. Fiala M, Gorzolka J, Wojnarová V, et al. Změny objemu a voltáže levé síně po komplexní ablaci pro perzistentní fibrilaci síní. Interv Akut Kardiol 2008;7:178-83.
    45. Chang SH, Tsao HM, Wu MH, et al. Morphological changes of the left atrial appendage after catheter ablation of atrial fibrillation. J Cardiovasc Electrophysiol 2007;17:47-52. Go to original source... Go to PubMed...
    46. Corradi D, Callegari S, Bemussi S, et al. Myocyte changes and their left atrial distribution in patients with chronic atrial fibrillation related to mitral valve disease. Human Pathol 2005;36:1080-9. Go to original source... Go to PubMed...
    47. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet 1989;1:175-9. Go to original source...
    48. The Boston area anticoagulation trial for atrial fibrillation investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
    49. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. Final results. Circulation 1991;84:527-39. Go to original source...
    50. Stroke prevention in atrial fibrillation investigators. Stroke prevention in atrial fibrillation study. Final results. Circulation 1991;84:527-39.
    51. Ezekowitz M, Bridgers S, James K, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med 1992;327:1406-12. Go to original source... Go to PubMed...
    52. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62. Go to original source...
    53. Lévy S, Maarek M, Coumel P, et al. Characterization of different subsets of atrial fibrillation in general practice in France: the ALFA study. The College of French Cardiologists. Circulation 1999;99:3028-35. Go to original source...
    54. Miyasaka Y, Barnes ME, Gersh BJ, et al. Time trend of ischemic stroke and mortality incidence in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study. Stroke 2005;36: 2362-6. Go to original source... Go to PubMed...
    55. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 2003;42:185-97. Go to original source...
    56. Oral H, Chugh A, Özaydin M, et al. Risk of thromboembolic events after percutaneous left atrial radiofrequency ablation of atrial fibrillation. Circulation 2006;114:759-65. Go to original source... Go to PubMed...
    57. Bulková V, Fiala M, Chovančík J, et al. Analýza nákladů na léčbu u pacientů s fibrilací síní v České republice. Cor Vasa 2008;50:23-7. Go to original source...

    Return to the content


    Cor et Vasa

    You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

    I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.


    No
    Yes